Evidence map›Paper›PMID 39263154›Full record

ArticleHeliyon2024

Targeting TAG-72 in cutaneous T cell lymphoma.

Vera J Evtimov, Maree V Hammett, Aleta Pupovac, Nhu-Y N Nguyen, Runzhe Shu, Carrie Van Der Weyden, Robert Twigger, Ian T Nisbet, Alan O Trounson, Richard L Boyd and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vera J EvtimovCartherics Pty Ltd, Notting Hill, Australia.
Maree V HammettCartherics Pty Ltd, Notting Hill, Australia.
Aleta PupovacCartherics Pty Ltd, Notting Hill, Australia.
Nhu-Y N NguyenCartherics Pty Ltd, Notting Hill, Australia.
Runzhe ShuCartherics Pty Ltd, Notting Hill, Australia.
Carrie Van Der WeydenCartherics Pty Ltd, Notting Hill, Australia.
Robert TwiggerSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Ian T NisbetCartherics Pty Ltd, Notting Hill, Australia.
Alan O TrounsonCartherics Pty Ltd, Notting Hill, Australia.
Richard L BoydCartherics Pty Ltd, Notting Hill, Australia.
H Miles PrinceSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Current monoclonal antibody-based treatment approaches for cutaneous T cell lymphoma (CTCL) rely heavily on the ability to identify a tumor specific target that is essentially absent on normal cells. Herein, we propose tumor associated glycoprotein-72 (TAG-72) as one such target. TAG-72 is a mucin-associated, truncated O-glycan that has been identified as a chimeric antigen receptor (CAR)-T cell target in solid tumor indications. To date, TAG-72 targeting has not been considered in the setting of hematological malignancies. Experimental design: CD3 Results: TAG-72 expression was significantly higher on total CD3 Conclusion: This study shows the first evidence of TAG-72 as a possible target for the treatment of CTCL.

Indexed as

CA 72-4CAR-T cellsCTCLTAG-72

Identifiers

PMID39263154
PMCPMC11386021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.